2025 Analysis: Opportunities and Risks in the Evolving Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Sector?
The market size for therapeutics of Attention Deficit Hyperactivity Disorder (ADHD) has been expanding positively over recent years. There is expected growth from $13.21 billion in 2024 to $13.97 billion in 2025, reflecting a 5.7% Compound Annual Growth Rate (CAGR). The market’s growth in the past years can be associated with factors such as increased awareness in diagnostics and screening programs, a surge in ADHD cases, improved treatment methods, expansion in health insurance coverage, and advancements in healthcare infrastructure.
The market for therapeutics treating attention deficit hyperactivity disorder (ADHD) is shaped to experience significant growth in the upcoming years. The market size is projected to reach “$17 billion by 2029, with a 5.0% compound annual growth rate (CAGR). The anticipated growth is linked to advancements in genetic research and individualized medicine, increased awareness of mental health issues, mental health campaigns at both global and national levels, the proliferation of telehealth, and the incorporation of behavioral therapies. The forecasting period will also be marked by innovative treatment technologies, concerted research and development efforts, incorporation of digital therapeutics, strategies based on precision medicine, and progression in drug delivery systems.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp
What Forces Are Driving The Growth Of The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?
The upward trend in attention-deficit hyperactivity disorder (ADHD) cases is anticipated to fuel the development of the ADHD therapeutics market. The surge in ADHD cases denotes an increase in the number of diagnosed patients over time. ADHD treatment strategies focus on addressing the multifaceted aspects of this neurodevelopmental disorder, with the goal of enhancing symptom control, minimizing functional impairment, and enriching the lives of those with ADHD. For example, in a report released by the US-based publishing company, the Guardian, in January 2023, it was estimated that about 170,000 known patients were receiving treatment for ADHD in 2022, marking a 20.4% growth from the 141,000 known patients in the same period in 2021. Thus, the escalating occurrence of ADHD is propelling the expansion of the attention-deficit hyperactivity disorder (ADHD) therapeutic market.
The attention deficit hyperactivity disorder (adhd) therapeutics market covered in this report is segmented –
1) By Drug Type: Stimulants, Non-Stimulants
2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy
3) By Age Group: Pediatric And Adolescent, Adult
4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce
Subsegments:
1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants
2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine
What Are The Leading Trends And Opportunities In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Sector?
Leading businesses in the ADHD therapeutics market have set their sights on creating and advancing digital technologies such as Endeavor over-the-counter (OTC) versions of digital therapeutics for ADHD in response to the growing need for digital solutions and remote healthcare services. Digital therapeutics entails using top-tier software programs to create evidence-based therapeutic methods aimed at preventing, managing, or treating various medical diseases or disorders. These methods can be used alone or in conjunction with traditional medical treatments. For instance, Akili, a digital health company based in the United States, introduced an over-the-counter (OTC) model of its digital therapeutic video game for adults living with ADHD in June 2023. Their OTC version, known as EndeavorOTC aims to enhance attention span, time management, and organization skills. This move distinguished itself following Akili’s FDA-authorised prescription video game treatment, EndeavorRx, intended for children diagnosed with ADHD. EndeavorOTC offers adults a non-pharmacological alternative for managing ADHD symptoms.
Which Companies Currently Dominate The Competitive Landscape In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?
Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical’s, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.
Which Geographic Regions Are Driving Demand In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?
North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=14042&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
